JP6925663B2 - Anti-glycation agent - Google Patents
Anti-glycation agent Download PDFInfo
- Publication number
- JP6925663B2 JP6925663B2 JP2020072085A JP2020072085A JP6925663B2 JP 6925663 B2 JP6925663 B2 JP 6925663B2 JP 2020072085 A JP2020072085 A JP 2020072085A JP 2020072085 A JP2020072085 A JP 2020072085A JP 6925663 B2 JP6925663 B2 JP 6925663B2
- Authority
- JP
- Japan
- Prior art keywords
- proteoglycan
- mass
- skin
- glycation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 210000002184 nasal cartilage Anatomy 0.000 claims description 11
- 241000972773 Aulopiformes Species 0.000 claims description 10
- 235000019515 salmon Nutrition 0.000 claims description 10
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 9
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 9
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 9
- 229940097043 glucuronic acid Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 2
- 102000016611 Proteoglycans Human genes 0.000 description 36
- 108010067787 Proteoglycans Proteins 0.000 description 36
- 239000000512 collagen gel Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 15
- 230000008602 contraction Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 102000016284 Aggrecans Human genes 0.000 description 3
- 108010067219 Aggrecans Proteins 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- -1 conventionally Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、化粧料や飲食品などで使用されるプロテオグリカンに係り、皮膚のタルミやシワ、ハリの改善等、皮膚の引きしめに有効なプロテオグリカンを有効成分とするコラーゲンゲル収縮促進剤、抗糖化剤及び皮膚外用剤に関するものである。 The present invention relates to proteoglycan used in cosmetics, foods and drinks, etc., and is a collagen gel contraction promoter and anti-glycation agent containing proteoglycan as an active ingredient, which is effective for tightening the skin such as improving skin tarmi, wrinkles and firmness. And skin external preparations.
加齢に伴い皮膚は弾力性が低下し、タルミやシワの発生等、いわゆる老徴を示す。 With aging, the elasticity of the skin decreases, and it shows so-called aging symptoms such as the occurrence of tarmi and wrinkles.
皮膚老化予防又は改善剤に関しては、従来、コラーゲンゲルの収縮を促進する薬剤としては、腐植土抽出物（特許文献１）、マルメロ種子抽出物（特許文献２）などが開示されているが、いずれも効果、安全性、安定性、価格等の観点において必ずしも十分であるとはいえなかった。 Regarding the skin aging preventive or ameliorating agent, conventionally, humus extract (Patent Document 1), malmero seed extract (Patent Document 2) and the like have been disclosed as agents that promote the contraction of collagen gel. However, it was not always sufficient in terms of efficacy, safety, stability, price, etc.
本発明は、効果、安全性、安定性、価格の面で優れた、コラーゲンゲル収縮促進効果を有するコラーゲンゲル収縮促進剤、抗老化につながる抗糖化作用を有する抗糖化剤、及びこのコラーゲンゲル収縮促進剤や抗糖化剤を皮膚に適用することによって皮膚のタルミやシワを予防又は改善しうる皮膚外用剤を提供することを課題とする。 INDUSTRIAL APPLICABILITY The present invention provides a collagen gel contraction promoter having a collagen gel contraction-promoting effect, an anti-glycation agent having an anti-glycation effect leading to anti-aging, and the collagen gel contraction, which are excellent in terms of efficacy, safety, stability and price. It is an object of the present invention to provide a skin external preparation capable of preventing or improving skin tarmi and wrinkles by applying an accelerator or an anti-glycation agent to the skin.
上記課題を解決するために、本発明の一つの態様は、グルクロン酸とＮ−アセチルガラクトサミンとを１：０．９〜１：１．１のモル比で有し、サケ鼻軟骨から酢酸を用いて抽出した、分子量２０万〜２００万のアグリカンタイプであるプロテオグリカンを有効成分とすることを特徴とする抗糖化剤であることを要旨とする。 In order to solve the above problems, one embodiment of the present invention has glucuronic acid and N-acetylgalactosamine in a molecular ratio of 1: 0.9 to 1: 1.1, and uses acetic acid from salmon nasal cartilage. The gist is that it is an anti-glycan agent characterized by containing proteoglycan, which is an aglycan type having a molecular weight of 200,000 to 2 million, as an active ingredient.
本発明の他の態様は、グルクロン酸とＮ−アセチルガラクトサミンとを１：０．９〜１：１．１のモル比で有し、サケ鼻軟骨から酢酸を用いて抽出した、分子量２０万〜２００万のアグリカンタイプであるプロテオグリカンを０．０１質量％〜１質量％含むことを特徴とする抗糖化剤であることを要旨とする。 Another aspect of the present invention comprises glucuronic acid and N-acetylgalactosamine in a molar ratio of 1: 0.9 to 1: 1.1 and extracted from salmon nasal cartilage using acetic acid, having a molecular weight of 200,000 to. It is a gist that it is an anti-glycation agent characterized by containing 0.01% by mass to 1% by mass of proteoglycan, which is a 2 million aggrecan type.
本発明の更に他の態様は、（ａ）０．０１質量％〜１質量％のプロテオグリカンと、（ｂ）２０質量％〜９９質量％の水性成分と、（ｃ）０質量％〜８０質量％の油性成分と、（ｄ）０質量％〜２０質量％の界面活性剤と、を含む皮膚外用剤であって、（ｅ）プロテオグリカンが、グルクロン酸とＮ−アセチルガラクトサミンとを１：０．９〜１：１．１のモル比で有し、サケ鼻軟骨から酢酸を用いて抽出した、分子量２０万〜２００万のアグリカンタイプであるプロテオグリカンであることを特徴とする皮膚外用剤であることを要旨とする。 Still another aspect of the present invention is (a) 0.01% by mass to 1% by mass of proteoglycan, (b) 20% to 99% by mass of an aqueous component, and (c) 0% by mass to 80% by mass. An external preparation for skin containing (d) 0% by mass to 20% by mass of a surfactant, and (e) proteoglycan is a mixture of glucuronic acid and N-acetylgalactosamine at a ratio of 1: 0.9. It is a skin external preparation having a molar ratio of ~ 1: 1.1 and being an aggrecan type proteoglycan having a molecular weight of 200,000 to 2 million extracted from salmon nasal cartilage using acetic acid. It is a summary.
本発明のコラーゲンゲル収縮促進効果を有するコラーゲンゲル収縮促進剤、抗老化につながる抗糖化作用を有する抗糖化剤、及びこのコラーゲンゲル収縮促進剤や抗糖化剤を用いた皮膚外用剤によれば、線維芽細胞コラーゲンマトリックスゲル構造の収縮を促すと共に糖化タンパク質の生成を抑制し、加齢に伴う皮膚の弾力やハリの低下、タルミやシワを予防又は改善することが可能である。 According to the collagen gel contraction-promoting agent having a collagen gel contraction-promoting effect, the anti-glycation agent having an anti-glycation effect leading to anti-aging, and the skin external preparation using the collagen gel contraction-promoting agent and the anti-glycation agent of the present invention. It promotes the contraction of the fibroblast collagen matrix gel structure and suppresses the production of glycated proteins, and can prevent or improve the elasticity and firmness of the skin, tarmi and wrinkles associated with aging.
以下、実施の形態をより具体的に説明するが、本発明の技術的思想を具体化するための方法を例示するものであって、本発明の技術的思想は、下記のものに特定するものではない。本発明の技術的思想は、特許請求の範囲に記載された請求項が規定する技術的範囲内において、種々の変更を加えることができる。 Hereinafter, embodiments will be described in more detail, but the method for embodying the technical idea of the present invention is exemplified, and the technical idea of the present invention is specified as follows. is not it. The technical idea of the present invention may be modified in various ways within the technical scope specified by the claims stated in the claims.
本発明のコラーゲンゲル収縮促進剤は、グルクロン酸とＮ−アセチルガラクトサミンを含む分子量２０万〜２００万のアグリカンタイプのプロテオグリカンを０．０１質量％〜１質量％含むコラーゲンゲル収縮促進剤を含むものである。又、本発明の抗糖化剤は、グルクロン酸とＮ−アセチルガラクトサミンを含む分子量２０万〜２００万のアグリカンタイプのプロテオグリカンを０．０１質量％〜１質量％を含むものである。プロテオグリカンはコアタンパク質にコンドロイチン硫酸等のグリコサミノグリカン糖鎖が結合した糖とタンパク質の複合体であり、コラーゲンやヒアルロン酸等と共に存在する細胞外マトリックスを構成する成分の一つであるが、プロテオグリカンそのものにコラーゲンゲル収縮促進効果や抗糖化作用があるとの報告は全く見られず、新規な知見であると共に食経験のある素材であることから安全性の観点からも極めて有用性は高いと思われる。 The collagen gel shrinkage accelerator of the present invention contains a collagen gel shrinkage promoter containing 0.01% by mass to 1% by mass of an aggrecan-type proteoglycan having a molecular weight of 200,000 to 2 million, which contains glucuronic acid and N-acetylgalactosamine. Further, the anti-glycation agent of the present invention contains 0.01% by mass to 1% by mass of an aglycan-type proteoglycan having a molecular weight of 200,000 to 2 million containing glucuronic acid and N-acetylgalactosamine. Proteoglycan is a complex of sugar and protein in which glycosaminoglycan sugar chains such as chondroitin sulfate are bound to core protein, and is one of the components constituting the extracellular matrix that exists together with collagen, hyaluronic acid, etc., but proteoglycan There are no reports that it has a collagen gel contraction-promoting effect or an anti-glycation effect, and it is considered to be extremely useful from the viewpoint of safety because it is a new finding and a material with eating experience. Is done.
プロテオグリカンの原料としては、ウシ、ブタ、ニワトリ、クジラ等の哺乳類や、サケ、サメなどの魚類等の軟骨や皮などがあり、その構造にはアグリカン、バーシカン、デコリンなど様々なタイプが知られているが、本発明が基礎とするプロテオグリカンは、サケの鼻軟骨由来のものであり、より好ましくはサケ鼻軟骨を原料に酢酸を抽出溶媒として用いて得られたアグリカンタイプのものである。その製法をはじめとする詳細については、特許第３７３１１５０号明細書に記載されており、また本発明で用いられるプロテオグリカンは、株式会社角弘プロテオグリカン研究所から「プロテオグリカン」の商品名で市販されている。 Raw materials for proteoglycans include mammals such as cows, pigs, chickens and whales, and cartilage and skin of fish such as salmon and sharks, and various types such as aggrecan, versican and decorin are known for their structures. However, the proteoglycan on which the present invention is based is derived from shark nasal cartilage, and more preferably an aglycan type obtained by using shark nasal cartilage as a raw material and acetic acid as an extraction solvent. Details such as the manufacturing method are described in Japanese Patent No. 3731150, and the proteoglycan used in the present invention is commercially available from Kakuhiro Proteoglycan Research Institute Co., Ltd. under the trade name of "proteoglycan".
本発明に係るプロテオグリカンは、サケ鼻軟骨を原料に酢酸を抽出溶媒として得られたものであるが、その分子量は、標準分子量マーカー（Ｓｔａｎｄａｒｄ（Ｐｕｌｌｕｌａｎ）、昭和電工）を用いた高速液体クロマトグラフにより（カラム：ＴＯＳＯＨＴＳＫｇｅｌＧ５０００ＰＷＸＬ７．８×３００,ＴＯＳＯＨＴＳＫｇｕａｒｄｃｏｌｕｍｎＰＷＸＬ６．０×４０、溶出液：２０ｍＭリン酸緩衝液（ｐＨ６．８）、流速：０．５ｍｌ/ｍｉｎ、カラム温度：４０℃）約５０万と見積もられた。本発明者らの糖鎖工学を専門とする研究者等の経験則によれば、分子量２０万〜２００万程度であれば、同様な効果が得られると推定できる。更に、分子量４０万〜１００万程度のプロテオグリカンであることが好ましい。 The proteoglycan according to the present invention was obtained by using salmon nasal cartilage as a raw material and using acetic acid as an extraction solvent, and its molecular weight was determined by a high performance liquid chromatograph using a standard molecular weight marker (Standard (Pullulan), Showa Denko). (Column: TOSOHTSKgelG5000PWXL7.8 × 300, TOSOHTSKgradcolumnPWXL6.0 × 40, Eluate: 20 mM phosphate buffer (pH 6.8), Flow velocity: 0.5 ml / min, Column temperature: 40 ° C.) Estimated to be about 500,000. rice field. According to the empirical rules of researchers specializing in sugar chain engineering of the present inventors, it can be estimated that the same effect can be obtained if the molecular weight is about 200,000 to 2,000,000. Further, it is preferably a proteoglycan having a molecular weight of about 400,000 to 1,000,000.
本発明に係るプロテオグリカンの成分分析においては、糖組成分析の結果、グルクロン酸とＮ−アセチルガラクトサミンの比は１：０．９乃至１：１．１であった。また、加水分解後、ニンヒドリン法によるアミノ酸分析装置（ＪＬＣ５００／Ｖ、日本電子社製）を用いてアミノ酸組成分析を行った結果、タンパク質含量は６〜７質量％であった。 In the component analysis of proteoglycan according to the present invention, as a result of sugar composition analysis, the ratio of glucuronic acid to N-acetylgalactosamine was 1: 0.9 to 1: 1.1. After hydrolysis, the amino acid composition was analyzed using an amino acid analyzer (JLC500 / V, manufactured by JEOL Ltd.) by the ninhydrin method. As a result, the protein content was 6 to 7% by mass.
本発明のコラーゲンゲル収縮促進効果及び抗糖化作用を有する皮膚外用剤は、０．０１質量％〜１質量％のプロテオグリカンと、２０質量％〜９９質量％の水性成分（水、エタノール、グリセリン、ブチレングリコール等）と、０質量％〜８０質量％の油性成分（ワセリン、スクワラン、ロウ等）と、０質量％〜２０質量％の界面活性剤（アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、非イオン界面活性剤）と、を含む。ここで、この皮膚外用剤に含まれるプロテオグリカンは、上述したように、グルクロン酸とＮ−アセチルガラクトサミンを含む分子量２０万〜２００万のアグリカンタイプである。上記必須成分であるサケ鼻軟骨を原料に酢酸を抽出溶媒として用いて得られたプロテオグリカン以外に、通常化粧品や医薬品等の皮膚外用剤に用いられる成分、例えば保湿剤、紫外線吸収剤、美白剤、各種皮膚栄養剤に加えて、油性成分や水等を必要に応じて適宜配合することができる。また本発明は、外皮に適用される化粧料、医薬部外品等、特に化粧料に広く適用することが可能であり、洗顔料、化粧水、乳液、クリーム、ジェル、美容液、パックやマスク等、様々な剤型において広く適用することが可能である。またさらには、メーキャップ化粧品としてのファンデーションや、ボディーソープや石けん等のトイレタリー製品、医薬部外品であれば軟膏など、広く適用でき、これらに限定されるものではない。 The skin external preparation having the collagen gel shrinkage promoting effect and the antisaccharifying effect of the present invention contains 0.01% by mass to 1% by mass of proteoglycan and 20% by mass to 99% by mass of aqueous components (water, ethanol, glycerin, butylene). Glycol, etc.), 0% by mass to 80% by mass of oily components (Vaseline, squalane, wax, etc.), and 0% to 20% by mass of surfactant (anionic surfactant, cationic surfactant, amphoteric surfactant, etc.) Agents, nonionic surfactants) and. Here, the proteoglycan contained in this external preparation for skin is an aglycan type having a molecular weight of 200,000 to 2 million containing glucuronic acid and N-acetylgalactosamine, as described above. In addition to proteoglycan obtained by using salmon nasal cartilage, which is an essential ingredient, as an extraction solvent, acetic acid is used as an extraction solvent. In addition to various skin nutrients, oily components, water, and the like can be appropriately added as needed. Further, the present invention can be widely applied to cosmetics applied to the outer skin, non-medicinal products, etc., particularly cosmetics, and is applicable to facial cleansers, lotions, milky lotions, creams, gels, beauty essences, facial masks and masks. It can be widely applied in various dosage forms. Furthermore, it can be widely applied to foundations as makeup cosmetics, toiletry products such as body soap and soap, and ointments for quasi-drugs, and is not limited thereto.
以下に実施例を示して本発明を具体的に説明するが、これは単に例示の目的で述べるものであり、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is merely described for the purpose of illustration, and the present invention is not limited to these Examples.
（サケ鼻軟骨由来酢酸抽出プロテオグリカンのコラーゲンゲル収縮促進効果）
線維芽細胞を包埋したコラーゲンゲルの収縮率を本発明の被験物質の添加時と非添加時で比較し、コラーゲンゲル収縮促進作用を評価した。氷冷下で、コラーゲンＩ−ＰＣ溶液（高研株式会社）を終濃度１ｍｇ／ｍｌ、３×ＤＭＥＭ培地を終濃度１倍、１×ＤＭＥＭ培地で調製した正常ヒト皮膚線維芽細胞の細胞懸濁液１．０×１０５ｃｅｌｌｓ／ｍｌ（終濃度）を泡立てないように穏やかに混合した後、２４ウェルプレートの各ウェルに０．８ｍｌずつ注入し、直ちに３７℃でゲル化させた。その後、異なる濃度のプロテオグリカン（添加濃度０、２００、４００、６００、８００μｇ／ｍｌ）を含有するＤＭＥＭ培地を加え、ウェル壁面からゲルを剥離しコラーゲンゲル収縮を行った。４８時間培養後、コラーゲンゲルの写真を撮影し、画像解析ソフトＩｍａｇｅＪによって画像解析してサンプル添加培養後のコラーゲンゲルの面積を測定した。ゲルの収縮状態を撮影した画像を図１に示す。無添加時のゲル収縮率を対照として、Ｄｕｎｎｅｔｔの検定により５％有意水準で各サンプルのゲル収縮率を比較した。ゲルの収縮率を評価した結果を図２に示す。
(Collagen gel contraction promoting effect of acetic acid extracted proteoglycan derived from salmon nasal cartilage)
The contraction rate of the collagen gel in which fibroblasts were embedded was compared between the time when the test substance of the present invention was added and the time when the test substance of the present invention was not added, and the collagen gel contraction promoting effect was evaluated. Cell suspension of normal human skin fibroblasts prepared with collagen I-PC solution (Koken Co., Ltd.) at a final concentration of 1 mg / ml and 3 × DMEM medium at a final concentration of 1 times under ice-cooling. after mixing liquid 1.0 × 10 5 cells / ml gently without creating bubbles (final concentration), it was injected by 0.8ml to each well of a 24 well plate and allowed to gel immediately 37 ° C.. Then, DMEM medium containing proteoglycans having different concentrations (additional concentrations of 0, 200, 400, 600, 800 μg / ml) was added, the gel was peeled off from the well wall surface, and collagen gel contraction was performed. After culturing for 48 hours, a photograph of the collagen gel was taken, and the area of the collagen gel after the sample addition culture was measured by image analysis using the image analysis software ImageJ. An image of the contracted state of the gel is shown in FIG. Using the gel shrinkage rate without addition as a control, the gel shrinkage rate of each sample was compared at a 5% significance level by Dunnett's test. The result of evaluating the shrinkage rate of the gel is shown in FIG.
コラーゲンゲルの収縮率は次式により算出した。
ゲル収縮率（％）＝１００−サンプル添加４８時間培養後のゲル面積／サンプル添加前のゲル面積×１００
サンプル添加前のコラーゲンゲル面積を１．９ｃｍ２（ウェル底の直径：１５．６ｍｍ）とした。
The shrinkage rate of collagen gel was calculated by the following formula.
Gel shrinkage rate (%) = 100-Gel area after culturing for 48 hours after sample addition / Gel area before sample addition x 100
The collagen gel area before adding the sample was 1.9 cm 2 (well bottom diameter: 15.6 mm).
図１より明らかなように、プロテオグリカンの濃度依存的にコラーゲンゲルを収縮した。ＩｍａｇｅＪによって画像解析してコラーゲンゲルの面積を定量した結果を図２に示す。無添加コントロール群と比較した結果、プロテオグリカンの濃度依存的に有意なコラーゲンゲル収縮効果が認められた。したがって、プロテオグリカンには皮膚のシワやタルミを予防し、改善する効果があると考えられ、化粧品への応用が可能である。 As is clear from FIG. 1, the collagen gel was shrunk in a concentration-dependent manner of proteoglycan. The result of image analysis by ImageJ to quantify the area of collagen gel is shown in FIG. As a result of comparison with the additive-free control group, a significant collagen gel contraction effect was observed depending on the concentration of proteoglycan. Therefore, proteoglycan is considered to have the effect of preventing and improving skin wrinkles and tarmi, and can be applied to cosmetics.
（サケ鼻軟骨由来酢酸抽出プロテオグリカンの抗糖化効果）
コラーゲン抗糖化アッセイキット（コスモ・バイオ）を用い、本発明に係るプロテオグリカン添加時と非添加時を比較検討することで、抗糖化作用を評価した。氷冷下、９６ウェルプレートに中和したコラーゲン溶液を５０μｌ／ウェルに分注し、３７℃インキュベーターで一晩静置しゲル化させた。コラーゲンゲル上に緩衝液もしくはフルクトース溶液を５０μｌ／ウェル重層した。その後、アミノグアニジン溶液（２２μｇ／ｍｌ）を陽性コントロールとして、異なる濃度のプロテオグリカン（０、１６０、４００、８００μｇ／ｍｌ）を添加し、プレートミキサーで攪拌後、３７℃インキュベーターで３０日間静置した後、蛍光強度（励起波長３７０ｎｍ、蛍光波長４４０ｎｍ）を測定し、各蛍光強度から糖化コラーゲン生成率を求めた。
(Anti-glycation effect of acetic acid-extracted proteoglycan derived from salmon nasal cartilage)
The anti-glycation effect was evaluated by comparing and examining the proteoglycan added and not added according to the present invention using a collagen anti-glycation assay kit (Cosmo Bio). Under ice-cooling, the neutralized collagen solution was dispensed into 50 μl / well in a 96-well plate and allowed to stand overnight in a 37 ° C. incubator for gelation. A buffer solution or fructose solution was overlaid on the collagen gel at 50 μl / well. Then, using an aminoguanidine solution (22 μg / ml) as a positive control, different concentrations of proteoglycan (0, 160, 400, 800 μg / ml) were added, stirred with a plate mixer, and allowed to stand in a 37 ° C. incubator for 30 days. , Fluorescence intensity (excitation wavelength 370 nm, fluorescence wavelength 440 nm) was measured, and the glycated collagen production rate was determined from each fluorescence intensity.
プロテオグリカンの糖化コラーゲン生成率を図３に示す。無添加コントロール群と比較した結果、プロテオグリカンにおいて濃度依存的に有意な抗糖化効果が認められた。したがって、プロテオグリカンには皮膚の老化を予防する効果があると考えられ、化粧品への応用が可能である。 The glycated collagen production rate of proteoglycan is shown in FIG. As a result of comparison with the additive-free control group, a significant concentration-dependent anti-glycation effect was observed in proteoglycan. Therefore, proteoglycan is considered to have an effect of preventing skin aging and can be applied to cosmetics.
老化により皮膚の弾力性やハリが低下し、タルミやシワの原因となるが、コラーゲンゲル収縮促進効果には、皮膚を引き締める作用が期待される。また抗糖化は、抗老化につながりアンチエイジング効果が期待されるものである。本発明の皮膚外用剤は、コラーゲンゲル収縮促進効果及び抗糖化作用を有し、それ自体が皮膚の改善、タルミ予防又は改善、皮膚引き締めに有効であり、あるいは皮膚老化予防又は改善のための化粧品、医薬品外品、医薬品であってもよく、化粧品、医薬品外品、医薬品等に配合して使用される素材又は製剤であってもよい。
Aging reduces the elasticity and firmness of the skin, causing tarmi and wrinkles, but the collagen gel contraction promoting effect is expected to have the effect of tightening the skin. In addition, anti-glycation leads to anti-aging and is expected to have an anti-aging effect. The external preparation for skin of the present invention has a collagen gel contraction promoting effect and an anti-glycation effect, and is itself effective for improving skin, preventing or improving tarmi, tightening skin, or a cosmetic product for preventing or improving skin aging. , Non-pharmaceutical products, pharmaceutical products, and may be materials or preparations used in combination with cosmetics, non-pharmaceutical products, pharmaceutical products, and the like.
Claims (5)
を０．０１質量％〜１質量％含むことを特徴とする抗糖化剤。 Proteoglycan, which has a molar ratio of glucuronic acid and N-acetylgalactosamine of 1: 0.9 to 1: 1.1 and is an aglycan type having a molecular weight of 200,000 to 2 million, extracted from salmon nasal cartilage using acetic acid. An anti-glycan agent containing 0.01% by mass to 1% by mass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072085A JP6925663B2 (en) | 2015-09-03 | 2020-04-14 | Anti-glycation agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015173453A JP2017048151A (en) | 2015-09-03 | 2015-09-03 | Collagen gel contraction promoter, anti-glycation agent and skin external preparation |
| JP2020072085A JP6925663B2 (en) | 2015-09-03 | 2020-04-14 | Anti-glycation agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015173453A Division JP2017048151A (en) | 2015-09-03 | 2015-09-03 | Collagen gel contraction promoter, anti-glycation agent and skin external preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020125319A JP2020125319A (en) | 2020-08-20 |
| JP6925663B2 true JP6925663B2 (en) | 2021-08-25 |
Family
ID=72084712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072085A Expired - Fee Related JP6925663B2 (en) | 2015-09-03 | 2020-04-14 | Anti-glycation agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6925663B2 (en) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0495010A (en) * | 1990-08-10 | 1992-03-27 | Nonogawa Shoji Kk | Cosmetic |
| JP3342050B2 (en) * | 1992-07-27 | 2002-11-05 | 有限会社野々川商事 | Cosmetics |
| JPH08253407A (en) * | 1995-03-17 | 1996-10-01 | Kotobuki Chem:Kk | Lotion |
| JP3731150B2 (en) * | 2000-08-22 | 2006-01-05 | 株式会社角弘 | Purification method of cartilage-type proteoglycan |
| JP3756838B2 (en) * | 2002-04-09 | 2006-03-15 | 日本メナード化粧品株式会社 | Topical skin preparation |
| JP2005239698A (en) * | 2004-02-27 | 2005-09-08 | Hajime Kozano | Skin care preparation for external use |
| JP4753922B2 (en) * | 2007-09-27 | 2011-08-24 | 肇 小座野 | Raw materials for cosmetics |
| EP2666467A4 (en) * | 2011-01-19 | 2014-11-19 | Univ Hirosaki | AQUATIC ANIMAL CARTILAGE EXTRACT |
| WO2014050717A1 (en) * | 2012-09-27 | 2014-04-03 | サントリーホールディングス株式会社 | Skin condition amelioration agent |
| JP6253047B2 (en) * | 2013-01-24 | 2017-12-27 | 地方独立行政法人青森県産業技術センター | Proteoglycan and cosmetics |
| JP6364281B2 (en) * | 2013-09-10 | 2018-07-25 | 花王株式会社 | Preventing or improving skin aging |
| JP2015025008A (en) * | 2014-10-20 | 2015-02-05 | 株式会社東洋新薬 | Anti-glycation composition |
-
2020
- 2020-04-14 JP JP2020072085A patent/JP6925663B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020125319A (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6326601B2 (en) | Peptides for skin renewal and methods of using said peptides | |
| CN101766546B (en) | Association of monosaccharides and C-glycoside derivatives and its use in cosmetics | |
| EP2164858B1 (en) | Kghk peptide, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
| CA3174981A1 (en) | Collagen compositions and methods of use thereof | |
| JP2002524487A (en) | Use of a peptide for scarring, moisturizing and improving skin appearance as a cosmetic or dermatological agent during natural aging or hyperaging (sun dermatitis, contamination) | |
| JP2010500282A (en) | Composition for promoting hyaluronic acid production comprising kaempferol and quercetin | |
| CN105263583B (en) | Cosmetic or dermatological uses of Polygonum serrata extract | |
| JP2008110927A (en) | Cosmetic containing royal jelly protein hydrolyzate | |
| JP6925663B2 (en) | Anti-glycation agent | |
| JP2018145106A (en) | Skin external compositions | |
| US20250025525A1 (en) | Octapeptide for topical application | |
| CN117897058A (en) | Collagen compositions and methods of use thereof | |
| JP2011042613A (en) | Anti-aging skin care preparation and anti-aging cosmetic | |
| KR20170128726A (en) | Cosmetics composition for anti-aging comprising agar-derived neoagarotetraose | |
| JP2017048151A (en) | Collagen gel contraction promoter, anti-glycation agent and skin external preparation | |
| Rodan et al. | Bioactive peptides | |
| US10406086B2 (en) | Moisturizer and cosmetic including the same | |
| JP2011219385A (en) | Antiaging agent, humectant, skin softener and external preparation for skin | |
| JP2024035284A (en) | Hyaluronic acid production promoter | |
| Schmidt et al. | Caring and Strengthening: the Global Skin Moisturization Strategy | |
| KR101219295B1 (en) | Composition for Promoting Production of Hyaluronic Acid Containing Musk T | |
| Chai et al. | Fish-Scale Collagen Peptides on Facial Skin Qualities and* Transdermal Penetration Efficiency | |
| KR20170049158A (en) | Cosmetic composition for improving skin wrinkle comprising octapeptide | |
| CN108992378A (en) | A kind of root of Dahurain angelica skin whitening, moisturizing antiallergic plant latex and preparation method thereof | |
| HK1146730A (en) | Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200513 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210428 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210720 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210728 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6925663 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |